APA (7th ed.) Citation

C, M., D, C., AE, R., E, J., L, H., H, C., . . . A, C. (2018). Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders, 9(4), 1703. https://doi.org/10.1007/s13300-018-0445-x

Chicago Style (17th ed.) Citation

C, Mathieu, Catrinoiu D, Ranetti AE, Johnsson E, Hansen L, Chen H, Garcia-Sanchez R, Iqbal N, and Celiñski A. "Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes." Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders 9, no. 4 (2018): 1703. https://doi.org/10.1007/s13300-018-0445-x.

MLA (9th ed.) Citation

C, Mathieu, et al. "Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes." Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, vol. 9, no. 4, 2018, p. 1703, https://doi.org/10.1007/s13300-018-0445-x.